Martina Khundakar - Senior Clinical Pharmacist Teresa Barnes - Lead Clinical Pharmacist - Specialist Care. Timothy Donaldson, Trust Chief Pharmacist
|
|
- Jasmin Holmes
- 6 years ago
- Views:
Transcription
1 Policy on Pharmacological Therapies Practice Guidance Note The use of Oral Anti-Cancer Medicines and Oral Methotrexate within - V03 V03 - Issued Issue 1 Dec 15 Planned review December 2018 PPT-PGN 09 Part of NTW(C)38- Pharmacological Therapies Author/Designation Martina Khundakar - Senior Clinical Pharmacist Teresa Barnes - Lead Clinical Pharmacist - Specialist Care Responsible Officer / Designation Timothy Donaldson, Trust Chief Pharmacist Section Contents Page No: 1 Introduction 1 2 Prescribing of Oral Anti-Cancer Medication 2 3 Administration of Oral Anti-Cancer Agents 3 4 Monitoring of Medication Methotrexate Inpatient Treatment of Patients Taking Methotrexate Prescribing of Methotrexate Administration of Oral Methotrexate in Hospitals Symptoms Indicating Possible Toxicity 6 1 Introduction 1.1 The prescribing and administration of oral anti-cancer medicines and oral methotrexate presents a significant risk to patients within Northumberland, Tyne and Wear NHS Foundation Trust (the Trust/NTW). 1.2 Medication which is prescribed at the wrong dose or frequency can result in death or significant morbidity. As a result, it is essential that the prescribing of these medicines takes place under the supervision of an appropriate specialist. 1.3 Treatment with oral anti cancer agents and methotrexate may be necessary for the continuing care of patients with concomitant physical illness, however the prescribing of these agents represents a significant deviation from the expertise and experience of prescribers, pharmacists and nursing staff working within the Trust. 1
2 1.4 The list of oral anticancer medicines currently used can be accessed at: These medicines are prescribed primarily as anticancer agents but may be prescribed for the treatment of other physical illnesses Methotrexate may also be prescribed for the treatment of rheumatoid and psoriatic arthritis, psoriasis and for the treatment of severe Crohn s disease (unlicensed indication). 2 Prescribing of Oral Anti-Cancer Medication 2.1 Treatment with oral anti-cancer medicines and methotrexate must be initiated by an appropriate specialist and not a doctor employed by the Trust. 2.2 Oral anticancer medicines may be prescribed under the direction of a cancer specialist working outside of NTW, provided that they take responsibility for the review of the patient and are able to provide advice to both medical and nursing staff. 2.3 A copy of the patient s treatment plan must be made available to those who are involved in the prescribing, dispensing and administration of oral anticancer agents. 2.4 In the majority of patients, methotrexate is given ONCE WEEKLY ON A SPECIFIED DAY. If prescribed more frequently than this, the prescription (medicine chart) MUST be validated and signed by a clinical pharmacist before being administered to the patient. 2.5 Where patients are to be initiated on an oral anticancer agent within the Trust following steps must be taken to minimise the risks to the patient. The patient should be given the opportunity to ask any relevant questions of the specialist prescribing the medicine or from another specialist familiar with the treatment regime. The patient must have ready access to the Patient Information Leaflet for the prescribed medication. The patient should be aware of the risks associated with treatment and any signs and symptoms that they may need to be aware of during treatment which could be an indication of a problem. The dosage, form and frequency of the medicine must be documented and communicated to the team in writing before any treatment is provided. Where this is not provided this should be requested to prevent unnecessary delay in treatment. Changes in dosage, formulation or frequency must be communicated in writing before these are implemented. Specialists must inform patients directly of any changes to their medication giving opportunity for questions. 2
3 3 Administration of Oral Anti-Cancer Agents 3.1 The pharmacy department will label these medicines with a purple Caution this is a cytostatic or cytotoxic agent sticker to aid recognition of such items. 3.2 Nursing staff must check that all medication is prescribed at the appropriate dosage and frequency before administering to the patient. This should be done by checking the patient s notes for the documented treatment plan. 3.3 Copies of the treatment plan should be made available to the Pharmacy department supplying the medication as an additional safeguard. 3.4 If the patient and medicine are unfamiliar to the nurse administering the medication a secondary check should be made with another colleague who knows the treatment plan and the patient before administration. It should be considered good practice to have a second person check the medicine being administered to the patient 3.5 Nurses involved in the handling of oral anticancer agents must wear appropriate protective clothing in accordance with the instructions provided by the pharmacy department. 3.6 If the dose is anything other than ONCE WEEKLY then the chart MUST have been validated and signed by a clinical pharmacist BEFORE the dose can be given. 4 Monitoring of medication 4.1 Any necessary monitoring of treatment must be stipulated in the treatment plan provided by the specialist. 4.2 The Trust may support the necessary monitoring where possible through regular blood tests as stipulated by the specialist in the treatment plan and assessment of adverse effects. 4.3 Nursing and medical staff must be warned of any additional monitoring that may be necessary during treatment and be aware of signs and symptoms of toxicity. 4.4 These signs/symptoms must be communicated with the named nurse responsible for the patient and all staff involved in his/her care. 4.5 The specialist must be consulted where there are any matters of concern with regard to the patient s treatment and physical health. 3
4 5 Methotrexate 5.1 Overdose of methotrexate for non-cancer treatment is classed as a never event by NHS England. Never Events are serious incidents that are wholly preventable as guidance or safety recommendations that provide strong systemic protective barriers are available at a national level and should have been implemented by all healthcare providers. Each Never Event type has the potential to cause serious patient harm or death. 5.2 The following safe practice checklist has been developed in response to the National Patient Safety Agency (NPSA) alert 03 (2004) updated as alert 13 (2006) Improving compliance with oral methotrexate guidelines issued to prevent incorrect dosing incidents. 5.3 There are many patients being treated with weekly subcutaneous injections of methotrexate for a variety of inflammatory conditions. Although not covered by the National Patient Safety Agency (NPSA) Safety Alert, it has been agreed that the above recommendations should be applied to these patients, as far as they are relevant. 5.4 Inpatient Treatment of Patients Taking Methotrexate The following should have been completed by the specialist prescribing team (e.g. rheumatology, dermatology) at the point of prescribing. It is the responsibility of NTW staff to ensure that patients have been given access to this information. Information on the risks and benefits of oral (and subcutaneous) methotrexate should be given to the patient (or parent/carer) Confirmation that the patient understands and consent should be sought Baseline monitoring tests should be conducted The arrangements for monitoring and the monitoring schedule should be explained to the patient The patient should be issued with a patient held monitoring booklet and information on methotrexate Inpatient staff should ensure that the prescribing, monitoring and administration of oral methotrexate are continued whilst the patient is an inpatient receiving treatment for co-morbid conditions Medicines reconciliation on admission to hospital must be conducted on admission to hospital (Please refer to the Trust s NTW(C)17 - Medicines Policy practice guidance note, UHM-PGN-02 - Prescribing Medicines The prescribing, monitoring and administration requirements for the methotrexate should be recorded in the patient s notes. 4
5 5.5 Prescribing of Methotrexate The prescriber is responsible for recording the correct dosage and frequency on the hospital drug administration chart (Kardex). Days on which a dose is not to be administered must be struck out (see example below) Prescriptions must state the dose of methotrexate and frequency of administration (usually weekly) Handwritten prescriptions and discharge summary information must be complete, legible and include the dosage form and strength. It is hospital trust policy that the only strength of methotrexate tablet used in the hospital is 2.5mg. Letters to GPs and outpatient/discharge prescriptions should clearly indicate the dose in terms of 2.5 mg tablets e.g. a 15 mg dose should be prescribed as Methotrexate 2.5mg tablets, take SIX tablets ONCE Weekly or Methotrexate, SIX 2.5mg tablets ONCE Weekly The results of any patient monitoring and changes in dose must be entered into the patient s hand held record It is hospital trust policy that the only strength of methotrexate tablet used in the hospital is 2.5mg. Letters to GPs and outpatient/discharge prescriptions should clearly indicate the dose in terms of 2.5 mg tablets e.g. a 15 mg dose should be prescribed as Methotrexate 2.5mg tablets, take SIX tablets ONCE Weekly or Methotrexate, SIX 2.5mg tablets ONCE Weekly Ensure details of dose changes recommended by specialists are recorded in the patient s monitoring booklet In the majority of patients, methotrexate is given ONCE WEEKLY ON A SPECIFIED DAY. If prescribed more frequently than this, the prescription (medicine chart) MUST be validated and signed by a clinical pharmacist before being administered to the patient. 5.6 Administration of Oral Methotrexate in Hospitals Follow the guidance detailed within the Trust s NTW(C)17 - Medicines Policy practice guidance note UHM-PGN-03 - Administration of Medicines. 5
6 5.6.2 In addition, ask the patient to confirm the following: That they are still taking methotrexate The dose of the medication How often they take the medicine and when they last took it. For conditions usually seen by this Trust methotrexate should be prescribed once weekly Record the medication given on the prescription/administration chart (Kardex) at the time of administration. A delay in recording administration can result in one or more additional doses being given. If the dose is anything other than ONCE WEEKLY then the chart MUST have been validated and signed by a clinical pharmacist BEFORE the dose can be given. 5.7 Symptoms Indicating Possible Toxicity Patients complaining of the following symptoms and taking methotrexate could have methotrexate toxicity or intolerance: Rash or oral ulceration Nausea and vomiting Diarrhoea Dry, persistent cough Breathlessness Any sign of infection, particularly sore throat Abnormal bruising 6
Improving compliance with oral methotrexate guidelines. Action for the NHS
Patient safety alert 13 Alert Immediate action Action Update Information request Ref: NPSA/2006/13 Improving compliance with oral methotrexate guidelines Oral methotrexate is a safe and effective medication
More informationCroydon Health Services NHS Trust (Working in Partnership) Shared Care Guideline: Prescribing Agreement
Shared Care Guideline: Prescribing Agreement Section A: To be completed by the hospital consultant initiating the treatment GP Practice Details: Name: Address: Tel no: Fax no: NHS.net e-mail: Consultant
More informationPharmacological Therapy Practice Guidance Note Medicine Reconciliation on Admission to Hospital for Adults in all Clinical Areas within NTW V02
Pharmacological Therapy Practice Guidance Note Medicine Reconciliation on Admission to Hospital for Adults in all Clinical Areas within NTW V02 V02 issued Issue 1 May 11 Issue 2 Dec 11 Planned review May
More informationNPSA Alert 03: Reducing the harm caused by oral Methotrexate. Implementation Progress Report July Learning and Sharing
NPSA Alert 03: Reducing the harm caused by oral Methotrexate Implementation Progress Report July 2006 Learning and Sharing CONTENTS Page 1 Background 3 2 Findings 4 Appendix 1 Summary of responses 6 Appendix
More informationORAL ANTI-CANCER THERAPY POLICY
ORAL ANTI-CANCER THERAPY POLICY Document Author Written By: Lead Oncology Pharmacist Authorised Authorised By: Chief Executive Officer Date: vember 2016 Date: 11 th April 2017 Lead Director: Executive
More informationSELF - ADMINISTRATION OF MEDICINES AND ADMINISTRATION OF MEDICINES SUPPORTED BY FAMILY/INFORMAL CARERS OF PATIENTS IN COMMUNITY NURSING
CLINICAL PROTOCOL SELF - ADMINISTRATION OF MEDICINES AND ADMINISTRATION OF MEDICINES SUPPORTED BY FAMILY/INFORMAL CARERS OF PATIENTS IN COMMUNITY NURSING RATIONALE Medication errors can cause unnecessary
More informationMETHOTREXATE TOXICITY
METHOTREXATE TOXICITY AN INQUIRY INTO THE DEATH OF A CAMBRIDGESHIRE PATIENT IN APRIL 2000 CAMBRIDGESHIRE HEALTH AUTHORITY JULY 2000 CONTENTS PAGE 1 Introduction 2 2 Background 2 3 Context 2 4 Purpose of
More informationClinical Check of Prescriptions in Ward Areas
Pharmacy Department Standard Operating Procedures SOP Title Clinical Check of Prescriptions in Ward Areas Author name and Gareth Price designation: Deputy Director of Pharmacy Clinical Services Pharmacy
More informationNHS Fife. Patient Group Direction for Named Community Pharmacists to Supply
Patient Group Direction for Named Community Pharmacists to Supply Senna tablets 7.5mg or Senna syrup 7.5mg/5ml (Total sennosides calculated as sennoside B) For patients aged 16 years and older prescribed
More informationEnsuring our safeguarding arrangements act to help and protect adults PRACTICE GUIDANCE FOR REPORTING MEDICATION INCIDENTS INTO SAFEGUARDING
Ensuring our safeguarding arrangements act to help and protect adults PRACTICE GUIDANCE FOR REPORTING MEDICATION INCIDENTS INTO SAFEGUARDING Contents Page 1.0 Purpose 2 2.0 Definition of medication error
More informationPOLICY FOR ANTICIPATORY PRESCRIBING FOR PATIENTS WITH A TERMINAL ILLNESS Just in Case
POLICY FOR ANTICIPATORY PRESCRIBING FOR PATIENTS WITH A TERMINAL ILLNESS Just in Case DOCUMENT NO: DN116 Lead author/initiator(s): Sarah Woodley Community Health Services Pharmacist sarah.woodley@ccs.nhs.uk
More informationWHAT are medication errors?
Healthcare Case Study: Errors Cause Mapping Problem Solving Incident Investigation Root Cause Analysis Errors Angela Griffith, P.E. webinars@thinkreliability.com www.thinkreliability.com Office 281-412-7766
More informationADMINISTRATION OF MEDICATION BY DELEGATION
ADMINISTRATION OF MEDICATION BY DELEGATION ROLE AND RESPONSIBILITY OF THE TEACHER TRAINING MANUAL Medication Training Manual Final 10-2-17 Page 1 of 17 MEDICATION ADMINISTRATION TRAINING OBJECTIVES UPON
More informationPrimary care attitudes to methotrexate monitoring
Quality in Primary Care 2012;20:443 7 # 2012 Radcliffe Publishing Research paper Primary care attitudes to methotrexate monitoring Rachel Byng-Maddick MBBS BSc MRCP (Rheum) Specialist Registrar in Rheumatology,
More informationRecommendations from National Patient Safety Agency alerts that remain relevant to the Never Events list 2018
Recommendations from National Patient Safety Agency alerts that remain relevant to the Never Events list 2018 January 2018 We support providers to give patients safe, high quality, compassionate care within
More informationPATIENT GROUP DIRECTION (PGD) FOR THE SUPPLY OF DOXYCYCLINE 100MG CAPSULES / TABLETS FOR THE FIRST- LINE TREATMENT OF CHLAMYDIA TRACHOMATIS INFECTION
This Patient Group Direction () must only be used by registered pharmacists who have been named and authorised by their organisation to practice under it. The most recent and in date final signed version
More informationOxfordshire Anticoagulation Service. Important information about anticoagulation with vitamin K antagonists Information for patients
Oxfordshire Anticoagulation Service Important information about anticoagulation with vitamin K antagonists Information for patients Page 2 Your information Name:... Address:......... or patient stickie
More informationPROPOSAL TO UPDATE NEAR PATIENT TESTING ENHANCED SERVICE
PROPOSAL TO UPDATE NEAR PATIENT TESTING ENHANCED SERVICE 1.0 ACTION BY AWMSG: The All Wales Medicines Strategy Group (AWMSG) meeting held on 15 th December 2010 considered and approved the recommendations
More informationSHARED CARE GUIDELINE: Unlicensed use of Mercaptopurine for the treatment of Inflammatory Bowel Disease.
LINCOLNSHIRE CLINICAL COMMISSIONING GROUPS in association with UNITED LINCOLNSHIRE HOSPITALS TRUST SHARED CARE GUIDELINE: Unlicensed use of Mercaptopurine for the treatment of Inflammatory Bowel Disease.
More informationCare Coordination and Care Programme Approach Practice Guidance Note Learning Disability Admissions Urgent Care Only V02
Care Coordination and Care Programme Approach Practice Guidance Note Learning Disability Admissions Urgent Care Only V02 Date issued Issue 2 Dec 15 Issue 3 Dec 17 Author/Designation Responsible Officer
More informationSafer use of anticoagulants: the NPSA patient safety alert Steve Chaplin MSc, MRPharmS
Safer use of anticoagulants: the NPSA patient safety alert Steve Chaplin MSc, MRPharmS Steve Chaplin describes the NPSA s anticoagulant patient safety alert and the measures it recommends for making the
More informationMedicines Reconciliation: Standard Operating Procedure
Clinical Medicines Reconciliation: Standard Operating Procedure Document Control Summary Status: Version: Author/Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic Aims Implementation
More informationManaging medicines in care homes
Managing medicines in care homes http://www.nice.org.uk/guidance/sc/sc1.jsp Published: 14 March 2014 Contents What is this guideline about and who is it for?... 5 Purpose of this guideline... 5 Audience
More informationTrust Standard for the Assessment and Management of Physical Health Practice Guidance Note Enteral Tube Feeding Overview V01
Trust Standard for the Assessment and Management of Physical Health Practice Guidance Note Enteral Tube Feeding Overview V01 Date Issued Planned Review PGN No: Issue 1 Aug 16 Issue 2 Nov 16 Aug 19 AMPH-PGN-02
More informationSocial care guideline Published: 14 March 2014 nice.org.uk/guidance/sc1
Managing medicines in care homes Social care guideline Published: 14 March 2014 nice.org.uk/guidance/sc1 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationSouth Staffordshire and Shropshire Healthcare NHS Foundation Trust
South Staffordshire and Shropshire Healthcare NHS Foundation Trust Document Version Control Document Type and Title: Authorised Document Folder: Policy for Medicines Reconciliation on Admission and on
More informationUnlicensed Medicines Policy Document
Unlicensed Medicines Policy Document Effective: February 2002 (Intranet 2006) Review date: February 2007 A. Introduction In order to ensure that medicines are safe and effective the manufacture and sale
More informationMedicine Management Policy
INDEX Prescribing Page 2 Dispensing Page 3 Safe Administration Page 4 Problems & Errors Page 5 Self Administration Page 7 Safe Storage Page 8 Controlled Drugs Best Practice Procedure Page 9 Controlled
More information1. Guidance notes. Social care (Adults, England) Knowledge set for medication. What are knowledge sets? Why were knowledge sets commissioned?
Social care (Adults, England) Knowledge set for medication 1. Guidance notes What are knowledge sets? Part of the sector skills council Skills for Care and Development Knowledge sets are sets of key learning
More informationAll Wales Multidisciplinary Medicines Reconciliation Policy
All Wales Multidisciplinary Medicines Reconciliation Policy June 2017 This document has been prepared by the Quality and Patient Safety Delivery Group of the All Wales Chief Pharmacists Group, with support
More informationPATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Cetuximab (+/- platinum-based chemotherapy) HOSPITAL NAME/STAMP: PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH:
More informationAzathioprine. Shared Care Agreement for the treatment of Ulcerative colitis and Crohn s disease with Azathioprine, March 2012 Page 1 of 6
Azathioprine Shared Care Agreement for the treatment of Ulcerative colitis and Crohn s disease with azathioprine, a copy of which must be supplied by the specialist to the GP at commencement, which will
More informationAMPH-PGN-10 (Part of NTW(C)29 Trust Standard for Physical Assessment and Examination Policy
AMPH-PGN-10 Practice Guidance Note Intramuscular Injection (IMI) V01 Date Issued Planned Review PGN No: Issue 1 Sep 2017 Sep 2020 AMPH-PGN-10 (Part of NTW(C)29 Trust Standard for Physical Assessment and
More informationReconciliation of Medicines on Admission to Hospital
Reconciliation of Medicines on Admission to Hospital Policy Title State previous title where relevant. State if Policy New or Revised Policy Strand Org, HR, Clinical, H&S, Infection Control, Finance For
More informationPATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Cetuximab (+/- Chemotherapy) PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier)
More informationPatient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CHOP 21 + RITUXIMAB
Patient identifier/label: Page 1 of 6 FORM CHOP 21 + RITUXIMAB Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St. Thomas Hospital King s College Hospital
More informationHow to Report Medication Safety Incidents from a GP Practice on the National Reporting and Learning System (NRLS)
pecialist Pharmacy ervice Medicines Use and afety How to Report Medication afety Incidents from a GP Practice on the National Reporting and Learning ystem (NRL) This document provides a quick explanation
More informationMedication Management Policy and Procedures
POLICY STATEMENT This policy establishes guidelines for ensuring safe and correct management of client medications in accordance with legislative and regulatory requirements and professional practice competency
More informationCompleting the NPA online Patient Safety Incident Report form: 2016
The National Pharmacy Association (NPA) Patient Safety Incident report form can be used within the community pharmacy to log patient safety incidents. The online form should not include any patientidentifiable
More informationLINCOLNSHIRE CLINICAL COMMISSIONING GROUPS in association with UNITED LINCOLNSHIRE HOSPITALS TRUST
LINCOLNSHIRE CLINICAL COMMISSIONING GROUPS in association with UNITED LINCOLNSHIRE HOSPITALS TRUST SHARED CARE GUIDELINE: Azathioprine covering use in Dermatology and Gastroenterology All prescribing of
More informationPage 17. Medication Management Policy and Practice Guidelines
Page 17 APPENDIX A Medication Management Policy and Practice Guidelines Index Scope Definition of medication Principles underpinning safe use of medications Procedure Guidelines Scope 1. Medication packaging
More informationGENERAL MEDICATION PROCEDURES
GENERAL MEDICATION PROCEDURES In situations where services will be provided in the person s own home or with their family, guardian / responsible party, medication storage, ordering and receiving medications
More informationPATIENT AGREEMENT TO SYSTEMIC THERAPY: GENERIC CONSENT FORM. Patient s first names. Date of birth. Job title
Patient identifier/label: Page 1 of 5 GENERIC CONSENT FORM Patient s surname/family name Patient s first names Date of birth Hospital Name: NHS number (or other identifier) Male Female Special requirements
More informationNon-Steroidal Anti-Inflammatory Drugs (NSAIDs) Communication Care Bundle Guide
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Communication Care Bundle Guide The Scottish Patient Safety Programme (SPSP) is a unique national initiative that aims to improve the safety and reliability
More informationPlease call the Pharmacy Medicines Unit on or for a copy.
Title: PATIENT GROUP DIRECTION FOR THE SUPPLY OF FLUCONAZOLE 150MG UNDER THE MINOR AILMENT SERVICE Identifier: Across NHS Boards Organisation Wide Directorate Clinical Service Sub Department Area This
More informationNew v1.0 Date: Cathy Riley - Director of Pharmacy Policy and Procedures Committee Policy and Procedures Committee
Clinical Pharmacy Services: SOP Document Control Summary Status: Version: Author/Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic Aims Implementation Date: Review Date: Key Words:
More informationThe Medicines Policy. Chapter 6: Standards of Practice. MISCELLANEOUS and DISCHARGE
Chapter 6: Standards of Practice MISCELLANEOUS and DISCHARGE V2.1 Date: October 2015 CHAPTER 6 CONTENTS 6.5. Miscellaneous... 3 6.5.1 Patients Moving Between Healthcare Trusts... 3 6.5.1.1 Transfer of
More informationExpiry Date: January 2009 Template Version: Page 1 of 7
YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Inclusion criteria: Exclusion criteria: Cautions/Need for
More informationSupporting self-administration of medication in the care home setting
B143. November 2016 2.0 Community Interest Company Supporting self-administration of medication in the care home setting Care home residents should have the opportunity to make informed decisions about
More informationManaging Medicines Policy
Managing Medicines Policy General Guidance: Policy for Administration of Medication in Schools and Early Years Settings 1 The Governors and staff of Townville Infants School wish to ensure that pupils
More informationReducing Medication Errors: National Update
Reducing Medication Errors: National Update Ahmed Ameer Medication Safety Officer Ahmed.Ameer@NHS.net Safer Medication Practice & Medical Devices Team 27 th January 2015 Agenda 1. Development of the National
More informationPATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Lenvatinib PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:
More informationPROTOCOL FOR THE ADMINISTRATION OF SENNA. Formulary and Prescribing Guidelines
PROTOCOL FOR THE ADMINISTRATION OF SENNA Formulary and Prescribing Guidelines Introduction This protocol allows for the administration of Senna by a registered nurse without a prescription from a doctor
More informationPATIENT GROUP DIRECTION (PGD) FOR
Antibiotic Oral (tablet/capsule/suspension) PATIENT GROUP DIRECTION (PGD) FOR YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Caution: This
More informationMEDICINES RECONCILIATION GUIDELINE Document Reference
MEDICINES RECONCILIATION GUIDELINE Document Reference G358 Version Number 1.01 Author/Lead Job Title Jackie Stark Principle Pharmacist Clinical Services Date last reviewed, (this version) 29 November 2012
More informationOral Ibrutinib (single agent)
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM IBRUTINIB Patient s surname/family name Patient s first names Date of birth Hospital Name: NHS number (or other
More informationPROCESS FOR INITIATING A SYRINGE DRIVER FOR COMMUNITY NURSE PATIENTS OUT OF HOURS
STANDARD OPERATING PROCEDURE PROCESS FOR INITIATING A SYRINGE DRIVER FOR COMMUNITY NURSE PATIENTS OUT OF HOURS Issue History Issue Version one Purpose of Issue/Description of Change To facilitate patients
More informationAdministration of Intrathecal Cytotoxic Chemotherapy in NHS Grampian
Administration of Intrathecal Cytotoxic Chemotherapy in NHS Grampian Lead Author/Coordinator: Jeff Horn / Sarah Howlett Macmillan Haematology CNS/ Pharmacist Reviewer: Gavin Preston Consultant Haematologist
More informationMedicines Management Strategy
Medicines Management Strategy 2012 2014 Directorate responsible for the strategy: Medical and Governance Directorate Staff group to whom it applies: All clinical staff and Trust managers Issue date: 30/6/12
More informationThis controlled document shall not be copied in part or whole without the express permission of the author or the author s representative.
This document is also available in large print and other formats and languages, upon request. Please call NHS Grampian Corporate Communications on (01224) 551116 or (01224) 552245. This controlled document
More informationPolicy for Anticipatory Prescribing and Just in Case Bags
Policy for Anticipatory Prescribing and Just in Case Bags This policy was developed by Milton Keynes End of Life Care Medicine Group and has been adopted by all partner organisations (MK Clinical Commissioning
More informationFOR MEDICINE ADMINISTRATION IN COMMUNITY NURSING
STANDARD OPERATING PROCEDURE FOR MEDICINE ADMINISTRATION IN COMMUNITY NURSING Issue History Issue Version One Purpose of Issue/Description of Change To promote safe and effective medicine administration
More informationMINNESOTA. Downloaded January 2011
MINNESOTA Downloaded January 2011 4658.1300 MEDICATIONS AND PHARMACY SERVICES; DEFINITIONS. Subpart 1. Controlled substances. "Controlled substances" has the meaning given in Minnesota Statutes, section
More informationPATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Lomustine PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:
More informationBest Practice Guidance for GP Practices, Community Pharmacists and Care Home Providers
Medicines Management in Care Homes Best Practice Guidance for GP Practices, Community Pharmacists and Care Home Providers 1. Communication The care home manager, community pharmacist and GP surgery should
More informationMEDICATION MONITORING AND MANAGEMENT Procedures
MEDICATION MONITORING AND MANAGEMENT Procedures Waiver Programs Purpose To support persons served in their own homes with their medication needs. Scope This procedure applies to all Waiver employees who
More informationNewfoundland and Labrador Pharmacy Board
Newfoundland and Labrador Pharmacy Board Standards of Practice Prescribing by Pharmacists August 2015 Table of Contents 1) Introduction... 1 2) Requirements... 1 3) Limitations... 1 4) Operational Standards...
More informationMedication Errors in Chemotherapy PORSCHA L. JOHNSON, PHARM.D. CLINICAL PHARMACIST II MEDSTAR WASHINGTON HOSPITAL CENTER SATURDAY, SEPTEMBER 17, 2016
Medication Errors in Chemotherapy PORSCHA L. JOHNSON, PHARM.D. CLINICAL PHARMACIST II MEDSTAR WASHINGTON HOSPITAL CENTER SATURDAY, SEPTEMBER 17, 2016 DISCLOSURE STATEMENT I have nothing to disclose regarding
More informationPATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Gemcitabine-Doxorubicin PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL
More informationPATIENT GROUP DIRECTION (PGD) FOR Metronidazole 400mg Tablets
Antibiotic Oral (tablet/capsule/suspension) PATIENT GROUP DIRECTION (PGD) FOR YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Caution: This
More informationMMPR034 MEDICINES RECONCILIATION ON ADMISSION TO HOSPITAL PROTOCOL
MMPR034 MEDICINES RECONCILIATION ON ADMISSION TO HOSPITAL PROTOCOL 1 Table of Contents Why we need this Protocol...3 What the Protocol is trying to do...3 Which stakeholders have been involved in the creation
More informationPATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Vinorelbine (oral) PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL
More informationExecutive Director of Nursing and Chief Operating Officer
Document Title Arrangements for Managing Patients Mental and Physical Health Needs across NTW and the Acute Hospital Trusts Reference Number Lead Officer Author(s) (name and designation) Ratified by NTW(C)15
More informationMethotrexate in General Practice Audit Methotrexate: Using audit to enhance safer use of toxic medication Good for patients, Good for doctors.
Methotrexate in General Practice Audit Methotrexate: Using audit to enhance safer use of toxic medication Good for patients, Good for doctors. AUTHORS Dr. Diarmuid Quinlan Dr. Paul Ryan Purpose of ICGP
More informationPatient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CYTARABINE CONTINUOUS INFUSION
Patient identifier/label: Page 1 of 6 CYTARABINE Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St. Thomas Hospital King s College Hospital Lewisham Hospital
More informationThe Prescribing, Monitoring and Administration of Depot / Long Acting IM Medication within Community Mental Health Services
Standard Operating Procedure 2 (SOP 2) The Prescribing, Monitoring and Administration of Depot / Long Acting IM Medication within Community Mental Health Services Why we have a procedure? Black Country
More informationPatient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM PAZOPANIB. Patient s first names.
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM PAZOPANIB Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St. Thomas
More informationSection 2 Medication Orders
Section 2 Medication Orders 2-1 Objectives: 1. List/recognize the components of a complete medication order. 2. Transcribe orders onto the Medication Administration Record (MAR) correctly use proper abbreviations,
More informationPatient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM TRASTUZUMAB (HERCEPTIN) Patient s first names.
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM TRASTUZUMAB (HERCEPTIN) Patient s surname/family name Patient s first names Date of birth Hospital Name: NHS number
More informationSection 7: Core clinical headings
Section 7: Core clinical headings Core clinical heading standards: the core clinical headings are those that are the priority for inclusion in EHRs, as they are generally items that are the priority for
More informationSystemic anti-cancer therapy Care Pathway
Network Guidance Document Status: Expiry Date: Version Number: Publication Date: Final July 2013 V2 July 2011 Page 1 of 9 Contents Contents... 2 STANDARDS FOR PREPARATION AND PHARMACY... 3 1.1 Facilities
More informationChecklists for Preventing and Controlling
Checklists for Preventing and Controlling Clostridium difficile Infection (CDI) This document has been developed to specifically assist senior management and all ward staff to take appropriate actions,
More informationJob Title Name Signature Date
Supply of Fluconazole 150mg capsule by Community Pharmacists working in Forth Valley Pharmacies under NHS Minor Ailment Service. Protocol Number 125 Version 5 Date protocol prepared: November 2014 Date
More informationSUPPLY BY PHARMACISTS OF A NON-PRESCRIPTION MEDICINAL PRODUCT CONTAINING LEVONORGESTREL (NORLEVO 1.5MG TABLETS) AS EMERGENCY HORMONAL CONTRACEPTION
SUPPLY BY PHARMACISTS OF A NON-PRESCRIPTION MEDICINAL PRODUCT CONTAINING LEVONORGESTREL (NORLEVO 1.5MG TABLETS) AS EMERGENCY HORMONAL CONTRACEPTION GUIDANCE FOR PHARMACISTS ON SAFE SUPPLY TO PATIENTS (This
More informationManagement of Reported Medication Errors Policy
Management of Reported Medication Errors Policy Approved By: Policy & Guideline Committee Date of Original 6 October 2008 Approval: Trust Reference: B45/2008 Version: 4 Supersedes: 3 February 2015 Trust
More informationPhysical Health Monitoring Clinic Berwick Patient Information Leaflet
Physical Health Monitoring Clinic Berwick Patient Information Leaflet Shining a light on the future Introduction This leaflet provides you with information that you will find useful whilst attending the
More informationSAFE Standard of Care
SAFE Standard of Care THE NEW UK STANDARD OF CARE BANISH MEDICATION ERRORS We all know that when medication is prescribed, dispensed and administered correctly it can dramatically improve the quality of
More informationElectronic Prescribing and emar. Jonathan Sheldon Consultant Physician and Clinical Lead for Electronic patient records
Electronic Prescribing and emar Jonathan Sheldon Consultant Physician and Clinical Lead for Electronic patient records AIMS To discuss the support needed for the successful conclusion of this project To
More informationAged residential care (ARC) Medication Chart implementation and training guide (version 1.1)
Aged residential care (ARC) Medication Chart implementation and training guide (version 1.1) May 2018 Prepared by and the Health Quality & Safety Commission Version 1, March 2018; version 1.1, May 2018
More informationDr Vincent Kirchner, MEDICAL DIRECTOR. Date Version Summary of amendments Oct New Procedure
OLANZAPINE DEPOT PROCEDURE OCTOBER 2017 Policy title Policy reference Policy category Relevant to Date published Implementatio n date Date last reviewed Next review date Policy lead Contact details Accountable
More informationConsultation Group: See relevant page in the PGD. Review Date: October 2015
Patient Group Direction For The Supply Of Trimethoprim For The Treatment Of Women With Uncomplicated Urinary Tract Infections By Nurses And Pharmacists Working Within NHS Grampian Community Pharmacies
More informationUnlicensed Medicines Policy
Unlicensed Medicines Policy This procedural document supersedes: PAT/MM 4 v.3 Policy and Procedure for the Use of Unlicensed Medicines Did you print this document yourself? The Trust discourages the retention
More information5. returning the medication container to proper secured storage; and
111-8-63-.20 Medications. (1) Self-Administration of Medications. Residents who have the cognitive and functional capacities to engage in the self-administration of medications safely and independently
More informationName Job Title Signed Date. This Patient Group Direction is operational from: Oct 2017 Review date: Aug 19. Expires on 31 st October 2019
PGD4017 PATIENT GROUP DIRECTION FOR THE SUPPLY OF ACICLOVIR TABLETS FOR THE TREATMENT OF GENITAL HERPES SIMPLEX INFECTIONS by registered nurses and midwives in Integrated Sexual Health services employed
More informationWhat is TB? Prevention is better than cure. You can get latent or active TB even if you have had a BCG vaccination
What is TB? Tuberculosis (TB) is an illness caused by bacteria. When someone with TB in their lungs coughs or sneezes, they send TB bacteria into the air. If you breathe in these bacteria, one of three
More informationTemplate (to be adapted by care home) Medication to be administered on a PRN (when required) basis in a care home environment
Template (to be adapted by care home) Medication to be administered on a PRN (when required) basis in a care home environment The PRN Purpose & Outcome Protocol (PRN POP) Background The term PRN (from
More information